Skip to content
Biodatica
Start free

Janssen Research & Development, LLC

Indianapolis, Indiana

OncologyPhase IIListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    May 13, 2026

    Hematologic Neoplasms · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

    ClinicalTrials.gov · NCT07572006 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Dec 26, 2025

    Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage · WITHDRAWN · sponsor: Janssen Research & Development, LLC · A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

    ClinicalTrials.gov · NCT05521087 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Dec 17, 2025

    Hemolytic Disease of the Fetus and Newborn · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

    ClinicalTrials.gov · NCT07194070 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Mar 21, 2025

    Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    ClinicalTrials.gov · NCT06651229 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Jan 14, 2025

    Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    ClinicalTrials.gov · NCT06618001 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Dec 19, 2024

    Relapsed or Refractory Multiple Myeloma · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT06604715 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    Feb 9, 2024

    Advanced Stage Solid Tumors · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

    ClinicalTrials.gov · NCT06255665 (opens the source filing in a new tab)

  8. Trial

    PHASE1 registered

    Dec 20, 2023

    Neoplasms · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

    ClinicalTrials.gov · NCT06150157 (opens the source filing in a new tab)

  9. Trial

    PHASE1 registered

    Dec 14, 2023

    Neoplasms, Advanced Solid Tumors · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-87890387 for Advanced Solid Tumors

    ClinicalTrials.gov · NCT06178614 (opens the source filing in a new tab)

  10. Trial

    PHASE1 registered

    Apr 26, 2023

    Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

    ClinicalTrials.gov · NCT05818683 (opens the source filing in a new tab)

  11. Trial

    PHASE1 registered

    Nov 22, 2022

    Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis · RECRUITING · sponsor: Janssen Research & Development, LLC · A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

    ClinicalTrials.gov · NCT05652335 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Sep 28, 2021

    Prostatic Neoplasms · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

    ClinicalTrials.gov · NCT05022849 (opens the source filing in a new tab)

  13. Trial

    PHASE1/PHASE2 registered

    May 19, 2021

    Acute Leukemia · RECRUITING · sponsor: Janssen Research & Development, LLC · A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

    ClinicalTrials.gov · NCT04811560 (opens the source filing in a new tab)

  14. Trial

    PHASE1 registered

    Nov 26, 2020

    Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    ClinicalTrials.gov · NCT04609826 (opens the source filing in a new tab)

  15. Trial

    PHASE1 registered

    Nov 20, 2020

    Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    ClinicalTrials.gov · NCT04540796 (opens the source filing in a new tab)

  16. Trial

    PHASE1 registered

    Mar 28, 2019

    Leukemia, Myeloid, Acute, Myelodysplastic Syndromes · COMPLETED · sponsor: Janssen Research & Development, LLC · A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    ClinicalTrials.gov · NCT03915379 (opens the source filing in a new tab)

  17. Trial

    PHASE1 registered

    Dec 16, 2017

    Hematological Malignancies · ACTIVE_NOT_RECRUITING · sponsor: Janssen Research & Development, LLC · Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT03399799 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources